Be part of our Research

News

Scalability of the iPSC technology for future drug discovery & therapy

June 22nd 2017

The EBiSC consortium invites you to the Workshop on "Scalability of the iPSC technology for future drug discovery & therapy" which will take place on 2-3 November 2017 at Fraunhofer-Forum in Berlin.

Read
News

Phenotypic profiling and iron overload of sensory neurons derived from Friedrich’s ataxi iPSC

June 12th 2017

Our poster 'Phenotypic profiling and iron overload of sensory neurons derived from Friedrich’s ataxi iPSC' will be presented at ISSCR 2017, the International Society for Stem Cell Research annual meeting in Boston, on Wednesday 14th June at 7.30pm by Rachel Steeg, PHD, Project Lead.

Read
News

Nature Methods publish Application Note - A humanized phenotypic screening platform for chronic pain

June 1st 2017

Censo Biotechnologies and Cellectricon have joined forces to develop a first-in-kind humanized drug discovery platform to target chronic pain. The platform is based on human induced pluripotent stem cell–derived neurons in combination with Cellectricon's Cellaxess® Elektra screening system.

Read
News

Launch of Censo Biotechnologies summer intern programme

May 22nd 2017

Censo Biotechnologies is delighted to welcome three recruits for its summer intern programme. Each recruit has been selected from the MSc course in Regenerative Medicine (Clinical and Industrial Delivery) run by Dr Paul Travers at the Scottish Centre for Regenerative Medicine.

Read
News

Protocol for neuronal differentiation of human iPSCs using a bioreactor

May 17th 2017

The aim of this study, in association with Fraunhofer UK, was to validate and refine a published protocol for neuronal differentiation using three dimensional aggregates, and to make the protocol easily scalable through the use of a benchtop bioreactor.

Read
News

Poster Presentation at ELRIG

May 15th 2017

The development of sensory neurons derived from human induced pluripotent stem cells (hiPSCs) with a relevant expression profile is described in our poster, presented in association with Cellectricon, at the 2nd ELRIG bi-annual conference on Advances in Cell Based Screening in Drug Discovery.

Read
News

Censo Biotechnologies joins The Milner Institute as an Affiliated Partner

April 24th 2017

The Milner Therapeutics Institute is a global therapeutic alliance based in Cambridge, dedicated to the conversion of basic science into therapies. Censo Biotechnologies is delighted to join The Institute as an Affiliated Partner and looks forward to developing new partnerships in both academic and industry.

Read
News

A humanized phenotypic screening platform for chronic pain - Join Our Webinar

February 27th 2017

Physiologically relevant human models of chronic pain are essential to developing new therapeutics and overcome poor translation between animal studies and the clinical setting. Join us, as co-host, in a free webinar on stem cell-based pain and CNS drug discovery to learn more.

Read
News

Cellectricon and Censo Biotechnologies introduce a joint technology access program utilizing high-quality Human iPSC-based discovery services for CNS and pain research

January 27th 2017

Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.

Read
News

Cellectricon and Censo Biotechnologies collaborate to offer high-quality Human iPSC-based discovery services for CNS and pain research

September 8th 2016

Mölndal, Sweden and Cambridge, UK – 8th September 2016 – Cellectricon AB, a leading provider of advanced cell-based discovery screening services, today announced a commercial collaboration with UK-based stem cell technology company Censo Biotechnologies Ltd. Under the agreement, the parties will provide a suite of high-quality Human iPSC based discovery services to support both preclinical neuroscience and chronic pain research.

Read